Jazz Pharmaceuticals (JAZZ) PT Raised to $206 at BMO Capital
Tweet Send to a Friend
BMO Capital raised its price target on Jazz Pharmaceuticals (NASDAQ: JAZZ) to $206.00 (from $201.00) while maintaining a Outperform rating.Analsyt ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
